<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307540</url>
  </required_header>
  <id_info>
    <org_study_id>HT3687</org_study_id>
    <nct_id>NCT01307540</nct_id>
  </id_info>
  <brief_title>Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients</brief_title>
  <official_title>Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      Study hypothesis: light therapy may prevent oral ulcers in bone marrow recipients.&#xD;
&#xD;
      Methods: patients will be treated with either active light-emitting device or inactive&#xD;
      light-emitting device. Daily treatment with light therapy will start at the beginning of the&#xD;
      conditioning regimen and will last until day 21 post-transplant. Each daily treatment last&#xD;
      about 5 minutes. Patients will be evaluated for oral mucositis and oral pain level on a&#xD;
      weekly basis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:&#xD;
&#xD;
      o Assessment of effectiveness of treatment with QRay1 in preventing oral mucositis in&#xD;
      patients undergoing hematopoietic stem cell transplantation (HSCT).&#xD;
&#xD;
      Secondary endpoint:&#xD;
&#xD;
        -  Assessment of mucositis associated- pain relief.&#xD;
&#xD;
        -  Assessment of safety of treatment with QRay1 (oral adverse events).&#xD;
&#xD;
        -  Assessment of the patients' acceptance of the device.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Double-blind, randomized, placebo-controlled, 2 groups (randomization ratio 1:1).&#xD;
&#xD;
      Duration of treatment:&#xD;
&#xD;
      Daily treatment. Study-treatment administration began at the initiation of conditioning&#xD;
      regimen (visit 1) and continued to day 28 or at least until day 21 if the patient had no&#xD;
      mucositis (WHO or OMAS = &quot;0&quot;)&#xD;
&#xD;
      Light radiation dose:&#xD;
&#xD;
      60-70mW/cm2 (administered over 3 treatment areas), starting with 45 seconds per surface,&#xD;
      increasing each day in intervals of 15 seconds, up to a maximum of 90 seconds per surface.&#xD;
&#xD;
      Evaluation plan:&#xD;
&#xD;
      Evaluation began before the conditioning regimen was initiated (visit 1) and continued weekly&#xD;
      until day 28 or until day 21 if the patient had no mucositis. A follow-up evaluation was&#xD;
      performed a month after discharge the patient. Unusual clinical presentation was addressed&#xD;
      whenever observed.&#xD;
&#xD;
      Criteria for evaluation:&#xD;
&#xD;
      Primary efficacy variable:&#xD;
&#xD;
      o Rate of absent of mucositis at any of the visits using WHO scale for mucositis and OMAS.&#xD;
&#xD;
      Secondary efficacy variables:&#xD;
&#xD;
        -  Severity of oral mucositis at any of the visits using WHO scale for mucositis and OMAS.&#xD;
&#xD;
        -  Severity of oral pain at any of the visits using WHO scale for mucositis and OMAS.&#xD;
&#xD;
        -  Safety (oral adverse events)&#xD;
&#xD;
        -  Patients' acceptance of the study drug on an 11-step ladder. Others&#xD;
&#xD;
        -  Compliance with standard oral care (chlorhexidine rinse, nystatin readymix, saline&#xD;
           mouthwash)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Oral Mucosal Ulceration</condition>
  <condition>Oral Mucositis</condition>
  <condition>Oral Lesion</condition>
  <arm_group>
    <arm_group_label>Active light therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive light therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>phototherapy</intervention_name>
    <description>low level light therapy, broad band light wavelengths.</description>
    <arm_group_label>Active light therapy</arm_group_label>
    <arm_group_label>Inactive light therapy</arm_group_label>
    <other_name>QRay1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No oral ulceration at baseline&#xD;
&#xD;
          -  At risk for oral mucositis due to the conditioning regimen to HSCT&#xD;
&#xD;
          -  Age above 18 years old&#xD;
&#xD;
          -  Karnofsky score &gt;60&#xD;
&#xD;
          -  Agree to participate in the study (signed an informed consent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Well-founded doubt about the patient's jurisprudence&#xD;
&#xD;
          -  Children&#xD;
&#xD;
          -  Sensitivity to light or treated with drugs which are sensitizers to light&#xD;
&#xD;
          -  Treatment with other experimental topical drug during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>March 1, 2011</last_update_submitted>
  <last_update_submitted_qc>March 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Sharon Elad, PI</name_title>
    <organization>Hadassah University Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Oral Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

